Having developed a patient-derived xenograft (PDX) model from the ascitic fluid of a stage 3 serous cystadenocarcinoma patient, and demonstrating that FRα expression was retained in these tumours, further efficacy studies were performed. The gene discussed is FOLR1; the disease is neoplasm.